120. An open-label comparative trial of SUBA-itraconazole (SUBA) versus conventional itraconazole (c-itra) for treatment of proven and probable endemic mycoses (MSG-15): a pharmacokinetic (PK) and adverse Event (AE) analysis

BACKGROUND: C-itra is the drug of choice for treatment of most non-CNS, non-life-threatening forms of endemic mycoses (EM), including histoplasmosis, blastomycosis, coccidioidomycosis, sporotrichosis and talaromycosis. SUBA represents a new formulation of itraconazole that utilizes nanotechnology to...

Descripción completa

Detalles Bibliográficos
Autores principales: Pappas, Peter G, Spec, Andrej, Miceli, Marisa, McGwin, Gerald, McMullen, Rachel, Thompson III, George R R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Oral Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8644912/
http://dx.doi.org/10.1093/ofid/ofab466.120

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8644912/
http://dx.doi.org/10.1093/ofid/ofab466.120

Ejemplares similares